IMCC

TORONTO and GLIL YAM, Israel, May 13, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced its financial results for the first quarter ended March 31, 2026. All amounts were reported in Canadian dollars, unless otherwise stated. For the three months ended March 31, 2026, the Company recorded revenues of $8.7 million, gross profit of $1.4 million, operating loss of $1.7 million, and a net loss of $2.5 million, or $0.38 per share. The Company also continued to advance its cost optimization initiatives, reducing general and administrative expenses by 22% year-over-year. The Company also maintained its focus on working capital discipline and liquidity management, supported by convertible note financings completed during the quarter ended March 31, 2026, and additional financings completed following quarter-end. Management remains focused on operational efficiencies, disciplined working capital management, and the continued evaluation of strategic opportunities to enhance the Company's long-term growth. The full Interim Financial Statements and Management's Discussion and Analysis are available on SEDAR+ and EDGAR. About IMC IMC (Nasdaq: IMCC) is an international company focused on building and scaling innovative businesses and technologies across global markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors. The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms, in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Disclaimer for Forward-Looking Statements This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, "forward-looking statements"). All information that addresses activities or developments that we expect to occur in...

TORONTO and GLIL YAM, Israel, March 31, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today reported its audited consolidated financial results as of and for the full year ended December 31, 2025. The Company achieved a major operational milestone by generating positive cash flow from operating activities of C$4.7 million for the year ended December 31, 2025, a significant turnaround from negative cash flow in 2024, while delivering high revenue growth in Germany, completing financing transactions, and strengthening its cash position. 2025 Key Highlights (All figures in CAD thousands): Revenue totaled $54,731, reflecting stability and demonstrating resilience despite ongoing challenges in Israel. Germany revenue surged more than 134% to $36,348 (up from $15,508 in 2024), now accounting for over 66% of total Group revenue. This growth underscores the success of the Company's EU-GMP-certified production and distribution platform following Germany's medical cannabis legalization. Gross profit increased approximately 15% to $9,686, driven by cost efficiencies, optimized supply chains, and higher-margin German sales. Cash flow from operating activities turned strongly positive at $4,716 (compared to negative cash flow of $1,077 in 2024), representing the first full year of positive operating cash flow in recent history and reflecting improved working capital management and operational discipline. Cash and restricted cash rose sharply to $3,309 (from $927 at year-end 2024), bolstered by strategic financings. Strengthened cash position through a private placement offering yielding net proceeds of $5,065, as well as the extension and partial conversion of convertible debentures. In line with its previously announced strategy to explore and introduce additional business activities aimed at enhancing long-term growth opportunities, the Company recently took a step toward diversification of its businesses. On March 17, 2026, IMCannabis announced the signing of a non-binding letter of intent to acquire 51% of Black Axe Technologies Spolka z Organiczona. ("Black Axe"), a Polish technology company specializing in advanced defense and intelligence solutions. This proposed transaction marks the Company's strategic entry into the high-growth defense and homeland security techn...

TORONTO and GLIL YAM, Israel, Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated. Q3 2025 Financial Highlights: Consistent Revenue for Q3 2025 and 2024 of $13.9 million. 13% Gross profit decrease vs. Q3 2024 of $2.7 million vs. $3.1 million. 13% Gross Margin decrease vs. Q3 2024 of 20% vs. 23%. $3.1 million One time goodwill and intangible asset impairment in Q3 2025 Operating expenses. Non IFRS Adjusted EBITDA loss of $0.6 million in Q3 2025 vs. $0.2 million in Q3 2024. Management Commentary "The first nine months of 2025 have been part of a transition year for the Company. In Germany, expected regulatory changes may have a negative effect on the market for our sales, and the impact of these regulatory changes on us is not yet known. In the third quarter of 2025 we recorded a non-cash impairment to align asset values with current conditions. In parallel, as part of our strategic review, we are assessing selective new business activities to broaden our growth avenues and support long-term value creation", said Oren Shuster, CEO of IM Cannabis Corp. Q3 2025 Financial Results Net loss in Q3 2025 was $3.9 million, compared to net loss of $1.1 million in Q3 2024. Net loss increase mainly due to goodwill and intangible asset impairment recorded at Q3 2025. Revenue for the third quarter of 2025 amounted to $13.9 million, similar to Q3 2024, while revenues for the first 9 months ended September 30, 2025, amounted to $39 million vs. $40.7 million in the same period of 2024. Gross profit for the third quarter of 2025 was $2.7 million, compared to $3.1 million in Q3 2024, a decrease of 13%. Gross margin for the third quarter of 2025 was 20%, compared to 23% in Q3 2024, a decrease of 13%. Total operating expenses in Q3 2025 were $6.9 million compared to $4.1 million in Q3 2024, an increase of 68%. The increase is mainly due to goodwill and intangible asset impairment recorded at Q3 2025. Net loss in Q3 2025 was $0.8 million, compared to net loss of $1.1 million in Q3 2024, excluding the one-time goodwill and intangible asset impairment. In total, net lo...

TORONTO and GLIL YAM, Israel, Nov. 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the third quarter 2025 ended September 30, 2025, on Thursday, November 13, 2025, before the market opens. About IM Cannabis Corp. IMC (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player. The IMC ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Company Contact: Anna Taranko, Director Investor & Public Relations IM Cannabis Corp. +49 157 80554338 [email protected] Oren Shuster, CEO IM Cannabis Corp. +972-77-3603504 [email protected] Logo - https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg View original content:https://www.prnewswire.com/news-releases/im-cannabis-to-report-third-quarter-2025-financial-results-on-thursday-november-13th-at-900am-et-302607073.html

IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights 14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M 306% Gross profit increase vs. Q2 2024 of $3.4M vs. $0.8M ($1.9M in Q2 2024 is due to inventory clearing and accruals) 371% Gross Margin increase vs. Q2 2024 of 27% vs. 6% Stable Operating Expenses with a 2% Operating Expenses increase vs. Q2 2024 of $3.8M vs. $3.7M EBITDA profit of $0.1M in Q2 2025 vs. EBITDA loss of $2.3M in Q2 2024 Management Commentary "The ongoing war in Israel and supply chain delays have created real challenges for our revenue in both Israel and Germany, the impact on our Q2 revenue was approximately $5 million — a figure we expect to recover in the coming quarters," said Oren Shuster, Chief Executive Officer of IMC. "In spite of these obstacles, we are encouraged by the strong profitability and margin growth we've achieved. These results underscore the strength of our long-term strategy and the resilience of our team, positioning us well for sustainable growth." "In Q2, we achieved a 306% increase in gross profit to $3.4 million compared to $0.8 million last year, alongside a 105% improvement in Non-IFRS Adjusted EBITDA to a profit of $0.1 million from a $2.3 million loss. These results reflect disciplined cost management, operational efficiency, and margin expansion, even amid a 14% revenue decline driven by the ongoing war in Israel and supply chain delays. We remain focused on strengthening our balance sheet and positioning the company for sustainable, profitable growth as market conditions normalize," added Uri Birenberg, Chief Financial Officer of IMC. Q2 2025 Financial Results Net loss in Q2 2025 was $0.2 million, compared to net loss of $3.5 million in Q2 2024. Revenues for the second quarter of 2025 were $12.7 million compared to $14.8 million in the second quarter of 2024, a decrease of 14%. The decrease is mainly due to accelerated growth in Germany of $3.3 million and offset by decre...

TORONTO and GLIL YAM, Israel, Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens. About IM Cannabis Corp. IMC (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player. The IMC ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Company Contact: Anna Taranko, Director Investor & Public Relations IM Cannabis Corp. +49 157 80554338 [email protected] Oren Shuster, CEO IM Cannabis Corp. +972-77-3603504 [email protected] Logo - https://mma.prnewswire.com/media/1742228/5439902/IM_Cannabis_Logo.jpg View original content:https://www.prnewswire.com/news-releases/im-cannabis-to-report-second-quarter-2025-financial-results-on-tuesday-august-12th-at-900am-et-302520577.html SOURCE IM Cannabis Corp.

Revenue: Q1 2025 revenue was 12.5 million CAD, up 4% from 12.1 million CAD in Q1 2024. Gross Margin: Improved by 87% compared to Q1 2024. Net Profit: Achieved a net profit of 0.2 million CAD in Q1 2025, compared to a loss of 6 million CAD in Q1 2024. Adjusted EBITDA: Profit of 0.6 million CAD in Q1 2025, compared to a loss of 2.2 million CAD in Q1 2024. German Revenue Growth: Increased by 569% versus Q1 2024. Israeli Revenue Decline: Decreased by 56% versus Q1 2024. Operating Expenses: Decreased by 56% to 3.3 million CAD in Q1 2025 from 7.4 million CAD in Q1 2024. Gross Profit: Increased by 94% to 3.4 million CAD in Q1 2025 from 1.8 million CAD in Q1 2024. Cash Balance: 1.4 million CAD as of March 31, 2025, up from 0.9 million CAD on December 31, 2024. Total Assets: 44,934 CAD as of March 31, 2025, an increase of 15% from December 31, 2024. Total Liabilities: 41,761 CAD as of March 31, 2025, an increase of 16% from December 31, 2024. Warning! GuruFocus has detected 6 Warning Signs with IMCC. Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. IM Cannabis Corp (NASDAQ:IMCC) achieved a net profit in Q1 2025, marking a significant turnaround from previous losses. The company reported an 87% improvement in gross margin compared to Q1 2024. Revenue from the German market increased by 569% versus Q1 2024, highlighting successful market expansion. Operating expenses decreased by approximately 56% compared to Q1 2024, indicating improved cost management. Adjusted EBITDA turned positive, with a profit of 0.6 million CAD compared to a loss of 2.2 million CAD in Q1 2024. Revenue from the Israeli market declined by 56% compared to Q1 2024, impacting overall revenue distribution. The decrease in Israeli revenue was partly due to the cancellation of the organin bill, resulting in a revenue drop of approximately 3.5 million CAD. Total liabilities increased by 16% as of March 31, 2025, compared to December 31, 2024. The company faces ongoing challenges in balancing its operations between different markets, as seen in the shifting focus from Israel to Germany. Despite profitability, the company still needs to secure additional sources of capital and financing to support future operations. Q: Why is the upcoming meeting to approve the 25% ownership of the new company important, especially given the cu...

IMC Delivers Net Profit and 87% Gross Margin Improvement in Q1, Reflecting Strategic and Operational Progress TORONTO and GLIL YAM, Israel, May 15, 2025 /CNW/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2024, unless otherwise stated. IMC also announces the intention to complete a non-brokered private placement of secured debentures. Q1 2025 Financial Highlights Net profit of $175K 94% Gross profit increase vs. Q1 2024 of $3.5M vs. $1.8M and 29% Gross profit increase vs. Q4 2024 of $2.7M 4% Revenue increase vs. Q1 2024 of $12.5M vs. $12.1M 50% decrease in operating expenses vs. Q1 2024 excluding the one-time Oranim revocation related losses of $3.3M vs. $6.6M and 56% decrease including Oranim 129% increase of Non-IFRS Adjusted EBITDA profit to $0.6M vs. loss of $2.2M Management Commentary "Q1 2025 is a clear inflection point for IMC," said Oren Shuster, Chief Executive Officer of IMC. "Achieving net profitability and an 87% improvement in gross margin year-over-year demonstrates the strength of the strategic and operational groundwork we laid in 2024—and reinforces our trajectory toward sustained, profitable growth" "IMC's Q1 2025 results mark a major turning point in our financial performance. We achieved net profitability, driven by a 94% increase in gross profit, a 56% reduction in operating expenses and a 4% increase in revenue year-over-year," said Uri Birenberg, Chief Financial Officer of IMC. "Our operating ratio improved significantly to 26%, down from 77% in Q1 2024, and our Non-IFRS Adjusted EBITDA grew to $0.6 million—up 129% from a $2.2 million loss a year ago. These results reflect the strength of our strategy and the discipline with which we are executing it." Operational Highlights The Company intends to complete a non-brokered private placement (the "Offering") of secured convertible debentures of the Company (each, a "Debenture") for aggregate proceeds of up to C$2,500,000. The Debentures will mature on the date that is 12 months from the date of issuance and will not incur interest except in the event of default. The Debentures are being issued to holders of debentures that mature on May 26, 2025. The...

TORONTO and GLIL YAM, Israel, May 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com within 24 hours after the call. Link for the zoom call: https://us02web.zoom.us/j/82140859987?pwd=bMnLyv9nV9C0vyIttzmLGrWmhkR5nY.1 About IM Cannabis Corp. IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player. The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Company Contact: Anna Taranko, Director Investor & Public Relations IM Cannabis Corp. +49 157 80554338 [email protected] Oren Shuster, CEO IM Cannabis Corp. +972-77-3603504 [email protected] Logo: https...

TORONTO and GLIL YAM, Israel, May 6, 2025 /CNW/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com within 24 hours after the call. Link for the zoom call: https://us02web.zoom.us/j/82140859987?pwd=bMnLyv9nV9C0vyIttzmLGrWmhkR5nY.1 About IM Cannabis Corp. IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player. The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Company Contact: Anna Taranko, Director Investor & Public Relations IM Cannabis Corp. +49 157 80554338 [email protected] Oren Shuster, CEO IM Cannabis Corp. +972-77-3603504 [email protected] Logo: https://mma....

Q4 2024 Caps a Year of Strategic and Operational Improvements for IMC with 25% Revenue Growth, 42% decrease in Operating Expenses, and $0.5M Adjusted EBITDA Profit TORONTO and GLIL YAM, Israel, March 31, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, is pleased to announce its financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all amounts are reported in Canadian dollars and are compared to the quarter ended December 31, 2023. The Company's audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying management's discussion and analysis (the "Q4 MD&A"), together with its Annual Report on Form 20-F, can be accessed by visiting the Company's website at https://investors.imcannabis.com/, and its SEDAR+ and EDGAR profiles at www.sedarplus.ca, and http://www.sec.gov/edgar, respectively. Annual and Q4 2024 Financial Highlights +25% increase in Q4 Revenue vs Q4 2023 and 11% increase annually. $0.5M profit Non-IFRS Adjusted EBITDA1 in Q4 2024 vs. Losses of $4.3M in Q4 2023. 87% losses decrease in 2024 to $1.1M vs. $8.0M in 2023. +183% increase in IMC Germany Revenue 2024 vs 2023, for a total of $15.5M in 2024 vs $5.5M in 2023. -42% decrease in operating expenses in Q4 2024 vs. Q4 2023, and 17% decrease annually in 2024 to $18.7M vs. $22.6M in 2023. Management Commentary "When looking at 2024, while I am very proud of the 183% growth IMC delivered in Germany, I am delighted with the progress we made internally both strategically and operationally," said Oren Shuster, Chief Executive Officer of IMC. "In Q4, with our positive adjusted EBITDA of $0.5M, we are starting to see the initial impact of the savings we initiated during 2024 through our active cost management and full integration. This gives us a very strong foundation leading into 2025, where we anticipate that Q1 will be the best quarter in sales we have had to date in Germany." "The consolidated profit & loss analysis reveals significant improvements in the Company's financial performance. Despite the temporary impact of inventory clearance on gross profit, the substantial 17% reduction in operating expenses has driven meaningful improvement in operating results," stated Uri Birenberg, Chief Financial Officer of IMC. "The Q...